Treatment & Guidelines
At 5 years, the mean aortic valve area and valve gradient were equivalent in the TAVI group and the surgical (sAVR) group:
Mean aortic valve area: p=0.29; Mean valve gradient: p=0.92.
No patients receiving TAVI experienced SVD which required surgical valve replacement.
At 2-year follow-up on the PARTNER 3 Trial of TAVI in low- risk patients, there was no change in mean gradient, aortic valve area or paravalvular regurgitation.4
See the full evidence for TAVI in low-risk severe AS patients
Durability data from the PARTNER 1A and 1B Trials found reinterventions with TAVI were infrequent and usually caused by reasons other than SVD. Only 20 patients (0.8%) required a reintervention of which 5 (0.2%) were due to SVD.
87.2% and 96.6% (competing risk analyses) of patients receiving TAVI had freedom from SVD and BVF at 8 years, respectively. With TAVI, the incidence of SVD was 3.2% and the incidence of BVF was 0.6%.
What could a TAVI referral mean for your severe AS patients?
With the expansion of SAPIEN 3 TAVI to low-risk patients, long-term durability data is of paramount importance. Clinical and echocardiographic follow-up of patients from the PARTNER 3 Trial will continue for up to 10 years.4
Manufactured using the same tissue processing as the Perimount Magna Ease which is regarded as the most durable surgical bioprosthesis the SAPIEN 3 valve was built on the proven SAPIEN platform and designed with patient needs in mind. More information can be accessed on the Edwards website.5
*Data from the PARTNER 1A Trial of TAVI in low-risk severe aortic stenosis patients.
Content relating to Tavi.today is intented for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.